
Opinion|Videos|January 8, 2025
Long-Term Considerations for PBC Treatment Options
Panelists discuss how sustained treatment success in primary biliary cholangitis (PBC) requires regular monitoring of biochemical response markers, assessing patient adherence, managing potential adverse effects, and making timely adjustments to treatment strategies based on individual patient responses to seladelpar and elafibranor.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- As new data emerge regarding the durability of response with seladelpar and elafibranor, what are the key long-term considerations for maintaining treatment efficacy in PBC?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
2
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
3
ADA 2026: Optimized Inhaled Insulin Dosing Outperforms Subcutaneous Analogs for Postprandial Glucose in T1D
4
FDA Grants Breakthrough Therapy Designation to Investigational Cannabis-Derived Therapy for Chronic Low Back Pain
5




































































































































